Capital Royalty Purchases Royalty Interest in Global Antifungal Treatment

In the fourth quarter of 2006, Capital Royalty acquired a royalty entitlement on a leading antifungal treatment from a global pharmaceutical company.

Capital Royalty worked with the royalty holder to complete the transaction on an aggressive timeline, which allowed the holder to meet its financial planning objectives. The smoothness of the due diligence and closing of the transaction enhanced Capital Royalty’s relationship with the royalty holder’s management team, leading to additional investment opportunities.